Serum Institute of India Collaborates with Univercells
Serum Institute of India (SII), the world’s largest vaccine manufacturer, has joined forces with Univercells, a Belgian biotech innovator, targeting a dramatic increase in accessibility to personalised cancer care. This partnership aims to bring cutting edge treatment options within reach…
Armex UK on Transporting Temperature-Sensitive Pharmaceuticals to Warmer Climates
Aramex UK has urged pharmaceutical companies exporting products overseas to be mindful about shipping to warmer climates. Temperature fluctuations arising from improperly configured refrigerated containers, unforeseen delays, or other operational issues can lead to product damage or loss, which has…
Novartis Tender Offer for MorphoSys AG Commences
Novartis published the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG (“MorphoSys”), including all shares represented by MorphoSys American Depositary Shares (the “Offer”), for an…
Unlocking The Potential of Africa’s Pharmaceutical Market
Written by: Magrietha Mallinson, Global Vertical Lead, Health at DP World. Africa’s growing population, falling mortality rates, and increasing demand for healthcare services make it a market with substantial growth opportunities for European pharmaceutical companies. To capitalise on this transregional…
Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round
Seaport Therapeutics, a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, have announced the closing of a $100 million oversubscribed Series A financing round. The round was co-led by ARCH Venture Partners and Sofinnova Investments along with…
Preci and Biopredic International to Partner
Preci and Biopredic International, (“Biopredic”) have announced a collaboration for the production of pooled suspension human hepatocytes. Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in…
.jpg?cb=edf6155c4e635dbb2c6d624d573ae5a5&w=1200)
Diagnostics Model Can Make Autologous Cell Therapy Manufacturing Work
Written by: Guillaume Wallart, CEO, CellQuest Advanced therapy medicinal products have yet to reach their industrial golden age. This is typified by the state of chimeric antigen receptor (CAR)-T cell therapies – these drugs work, but we don’t yet know how…
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine
Transgene and NEC Corporation have announced that new data will be presented on TG4050, an individualised neoantigen cancer vaccine, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. These data are highlighted in the AACR press conference being held today and in a…
How Efficient Logistics can Change the Lives of Rare Disease Patients
Dr. Danial Arkwell, Head of Global Key Accounts, Pharma at Envirotainer highlights the vital role of efficient logistics in getting orphan drugs to patients in desperate need. There are approximately eight thousand rare diseases in the world and many of…
Tower Cold Chain Launch Live Tracking and Monitoring
Tower Cold Chain has unveiled an innovative live tracking feature in collaboration with ELPRO – a global leader in monitoring solutions for pharmaceutical and life science industries. This partnership enhances Tower’s advanced passive temperature-controlled containers, offering customers near real-time insights…
.jpg?cb=a3eb8c37e0b2bfd3faa80852bfec7f3f&w=1200)
MHRA Approves Combined Antibiotic Cefepime/Enmetazobactam
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the combined antibiotic cefepime/enmetazobactam (Exblifep 2 g/0.5 g powder for concentrate for solution for infusion) to treat adult patients with complicated infections of the urinary tract (bladder and kidneys) and…
Idorsia Announce Scottish Medicines Consortium has accepted QUVIVIQ
Idorsia UK have announced that the Scottish Medicines Consortium (SMC) has accepted QUVIVIQ (daridorexant) for restricted use within NHS Scotland for the treatment of adult patients with insomnia characterised by symptoms present for at least three months and considerable impact on…
.jpg?cb=281da82624c7b030fce0dd1aba28ea35&w=1200)
Novo Nordisk to Acquire Cardior Pharmaceuticals
Novo Nordisk and Cardior Pharmaceuticals have announced that Novo Nordisk has agreed to acquire Cardior for up to €1.025bn, including an upfront payment and additional payments if certain development and commercial milestones are achieved. Cardior is a leader in the…
.jpg?cb=4aeed20e12ffb2500cf3f934c211895c&w=1200)
FDA Approve Abbvie Ovarian Cancer Therapy
AbbVie have announced that the U.S. FDA has granted full approval for ELAHERE (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies. Patients…
Gene Therapy: Viral Vector Technology Innovators Prepare for Take-Off
Written by: Justin Wilson at Withers & Rogers. With more gene therapy clinical trials securing authorisation and getting underway globally, innovators are focusing on developing viral vector carrier technologies that are safer and easier to manufacture at scale, cost efficiently. Viral vectors,…
Employing Generative AI to Transform Regulatory Intelligence Insights and Processes
There is a real opportunity for Artificial Intelligence to maximise Life Sciences companies’ investment in regulatory data management. ArisGlobal’s Agnes Cwienczek & Renato Rjavec set out practical examples of artificial intelligence (AI) and Generative AI delivering tangible benefits. As life…
Caris Life Sciences Announces Partnership with Merck KGaA
Caris Discovery, the therapeutic research arm of Caris Life Sciences announced a multi-year strategic partnership with Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the U.S. and Canada, to accelerate the discovery and development of first-in-class…
Getinge and CellRev Launch Livit ACE Platform
Getinge has partnered with the bioprocessing company CellRev in the development of a continuous cell processing platform called Livit ACE (Adherent Cell Expansion). “Both our companies are dedicated to helping the development of life-saving therapies gain momentum. CellRev’s technology combined…
Astellas Breaks Ground on New €330 Million Facility in Ireland
Astellas Ireland, a wholly owned subsidiary of Astellas Pharma, held a ceremony to mark the breaking of the ground and start of construction for its new €330 million, facility at Kerry Technology Park, Tralee, Co. Kerry. The ceremony, held at the…
.jpg?cb=d005e7f0548a29ccceda53c4566023e6&w=1200)
Roche Receive FDA Approval for Molecular Test to Screen for Malaria
Roche have announced that the U.S. FDA have approved the cobas Malaria test for use on the cobas 6800/8800 Systems. This approved test can aid healthcare professionals in reducing potential risks of patient infection from transfused blood products. The cobas Malaria test provides…
Building A Sustainable Future for the Biopharma Industry
Written by: Maria Elena Gasperini, Director of Sustainability Life Sciences, Jacobs. As part of the global effort to address climate change, the biopharma industry is committed to decarbonising its operations and making manufacturing more sustainable. To support this seismic shift, biopharma…
.jpg?cb=3c893c519caf8a8aadc5cd1144d72415&w=1200)
Bespak Complete Inhaled and Nasal Drug Delivery Business Separation from Recipharm
Bespak have announced the completion of the transaction to separate Recipharm’s former Advanced Delivery Systems Business Unit from the Recipharm Group to form a new standalone company. Both Bespak and Recipharm are backed by EQT Private Equity. The spin-out has created…
.jpg?cb=f0505c795d6693a590bd71afcaa53368&w=1200)
Automation Means a Scalable Supply Chain for Clinical Trials
Written by: Paul Knight, Managing Director of CME Automation Systems One of the biggest challenges facing the life sciences industry is how to implement automated ‘just-in-time’ clinical supply chains that will increase speed, flexibility, and efficiency in clinical trial drugs…
Corteria Pharmaceuticals Announces Initiation of Phase 1 Study
Corteria Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of transformative therapies for heart failure and obesity, have announced the initiation of its Phase 1 study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the…
Upperton Pharma Open New Development and GMP Manufacturing Facility
UK-based contract development and manufacturing organisation Upperton Pharma Solutions was joined by Oxford/AstraZeneca COVID-19 vaccine co-inventor Professor Dame Sarah Gilbert, biotech industry representatives and local leaders to celebrate the official opening of a new 50,000 square foot development and GMP manufacturing…
Ubiquigent and Debiopharm Enter Agreement
Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, have announced an agreement with Debiopharm, a biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure…
.jpg?cb=2fc78f770fc516d3d6563d377800203b&w=1200)
Abilify Maintena (Aripiprazole) Approved in the EU
Otsuka Pharmaceutical Europe and H. Lundbeck A/S have announced that the European Commission (EC) has approved Abilify Maintena 960 mg (aripiprazole) as a once-every-two-months long-acting injectable (LAI) formulation for the maintenance treatment of schizophrenia in adult patients stabilised with aripiprazole. The EC decision…
Viking Therapeutics Announce Weight Loss Tablet Phase I Results
Viking Therapeutics have announced positive results from the company’s Phase 1 multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735, a dual agonist of the glucagon-like peptide 1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development…
Aragen Operationalises Biologics Indian Manufacturing Facility
Aragen has operationalised the first phase of its biologics manufacturing facility in Bangalore, India through its 100% subsidiary, Aragen Biologics Pvt Ltd. The facility is being set up at an investment of $30 million. It has also executed its first small-scale…
European Medicines Agency Recommends Authorisation of Neoatricon
BrePco Biopharma (BPCO) have announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a paediatric use marketing authorisation (PUMA) for the use of Neoatricon intended for the…
Akebia Receives FDA Approval of Vafseo
Akebia Therapeutics have announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily…
Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program
Blackstone have announced a new collaboration with Moderna through a development and commercialisation funding agreement where funds managed by Blackstone Life Sciences and will provide up to $750 million to fund Moderna’s influenza program. “Moderna has demonstrated a remarkable ability to impact human…
FDA Approves MSD’s WINREVAIR – European Pharmaceutical Manufacturer
MSD have announced that the U.S. FDA has approved sotatercept-csrk (U.S. Brand Name: WINREVAIR, for injection, 45mg, 60mg) for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class…
Lonza Expands Service Offering for Spray-Dried Biologics for Pulmonary Delivery
Lonza have announced an expansion of its service offering for spray-drying of proteins for pulmonary delivery. The new offering provides clinical and commercial manufacturing services at a kilogram scale from Lonza’s Bend (US) site, home to Lonza’s Centre of Excellence for…
.jpg?cb=7827d04e97302b7e7af5df1d6cd9b383&w=1200)
Bio-Rad Launches Validated Antibodies for Rare Cell and Circulating Tumour Cell Enumeration
Bio-Rad Laboratories have announced the launch of validated antibodies for rare cell and circulating tumour cell (CTC) enumeration. Validated for use with Bio-Rad’s Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive…
.jpg?cb=9713fb473a6581f24db4ec7aea19751e&w=1200)
Exothera Pledges to Fast-Track RNA Therapies with North American Expansion
Exothera has launched its game-changing nucleic acids service offering, powered by the world’s first continuous-batch RNA production platform, Ntensify. Developed by Exothera sister company Quantoom Biosciences, the Ntensify platform fast-tracks the production of higher quality and more cost-effective RNA therapeutics, delivering significant advantages at…
PhaSER Biomedical Agree Partnership with Sanders Tri-Institutional Therapeutic Discovery Institute
PhaSER Biomedical has agreed a long-term partnership with the Sanders Tri-Institutional Therapeutic Discovery Institute (TDI) to enhance the institute’s groundbreaking pre-clinical drug discovery research. Headquartered in New York, TDI is a unique partnership consisting of three world-renowned scientific and medical institutions;…
Actylis and Novo Nordisk Pharmatech to Partner
Actylis and Novo Nordisk Pharmatech A/S have entered into an agreement for the distribution of pharmaceutical grade Benzalkonium Chloride (BKC) to the pharmaceutical and medical device markets in Germany, Spain, Portugal, UK and Ireland. Ian Jennings, SVP-President Europe at Actylis…
Vicore Announces FDA Breakthrough Device Designation for Almee
Vicore Pharma Holding AB have announced FDA Breakthrough Device Designation status for Almee, a 9-week digital cognitive behavioural therapy (CBT), to be used as an adjunct treatment of anxiety symptoms related to PF. The FDA Breakthrough Devices Program designates those medical devices that are evaluated as…
Roquette to acquire IFF Pharma Solutions
Roquette have announced an agreement to acquire IFF Pharma Solutions, a worldwide producer of excipients for oral dosage solutions. The combination of the two complementary businesses will rebalance the company’s portfolio around the two pillars of Health and Nutrition. It will…
.jpg?cb=1ff86aaaead56b4176255d3412e3dafb&w=1200)
Lonza Signs Agreement to Acquire Large-Scale Biologics Site From Roche
Lonza have announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity to meet demand for commercial mammalian…
Owkin Expands Collaboration with Sanofi
Owkin, the first end-to-end TechBio unicorn that provides AI-driven precision drug discovery, development and diagnostics by matching new biology to new populations, has announced the expansion of their collaboration with Sanofi to include immunology. In their work with Sanofi on target…
Hovione and GEA Strengthen Partnership
Hovione and GEA have announced the next stage of their partnership, with new development agreements, the launch of the ConsiGma CDC flex as well as the installation of a new lab-scale R&D Continuous Tableting rig in Hovione´s facilities in Portugal. The two companies’…
Novo Nordisk’s Awiqli Recommended for Approval by European Regulatory Authorities
Novo Nordisk have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation for Awiqli (the brand name for once-weekly basal insulin icodec) for treatment of diabetes in adults….
FDA Leads the Charge for Diversity in Clinical Trials
It’s long been a concern for scientists and regulators that drugs are intended for use by anyone but are predominantly tested on one group – white men. This could change because of legislation introduced in the U.S. requiring Diversity Action…
Element Launches Pharmaceutical Testing Service
Element have announced the launch of its Rapid Response Pharmaceutical Testing Service from its Manchester Life Sciences laboratory. This offering will support the pharmaceutical industry by providing expedited and comprehensive testing solutions for customers worldwide to meet the demands of today’s…
SolasCure Awarded £405K Innovate UK Biomedical Catalyst Grant
SolasCure has been awarded a highly competitive Biomedical Catalyst Grant for industry-led research and development (R&D) from Innovate UK. The funding, totalling £405K, will support the continued clinical development of SolasCure’s first investigational product, Aurase Wound Gel, a hydrogel containing tarumase…
WHO Urges Scale-Up of TB Investments
Ahead of World Tuberculosis (TB) Day, which is marked on 24 March, WHO has released an investment case for TB screening and preventive treatment. A modelling study developed with Governments of four countries – Brazil, Georgia, Kenya and South Africa –…
NVIDIA and Cognizant Announce AI Pharma Partnership
Cognizant is advancing the application of generative AI (gen AI) technology with the NVIDIA BioNeMo platform to solve complex challenges of drug discovery in the life sciences industry, such as improving productivity in the development process and increasing the speed at…
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics
Bristol Myers Squibb have announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. With the acquisition’s completion, Karuna shares have ceased trading on the Nasdaq Global Select Market and Karuna is now a wholly owned subsidiary of Bristol…
.jpg?cb=85b1d2c4b768d0044356e3a7638a6459&w=1200)
European Commission Approves Pfizer’s PREVENAR 20
Pfizer Inc have announced that the European Commission (EC) has granted marketing authorisation for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20, for active immunisation for the prevention of invasive disease, pneumonia and…
Novartis Invest $256 million in Singapore Biopharmaceutical Manufacturing Facility
Novartis recently announced it broke ground for the expansion of its biopharmaceutical manufacturing plant in Singapore. The $256 million investment will facilitate Novartis in deploying digital and automation solutions to enhance manufacturing productivity, improve operational efficiency, and upskill the workforce. The…
.jpg?cb=50f5e515288bd0c4f496ef8ec88af7fb&w=1200)
AstraZeneca to acquire Amolyt Pharma
AstraZeneca have announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s…
Mission Therapeutics raises £25.2 million
Mission Therapeutics have announced it has raised £25.2 million to progress the clinical development of its drug candidates. The financing was jointly led by existing investors Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, and Rosetta Capital. Mission plans…
Vaccine makers to get VR-assisted training centre of excellence
The RESILIENCE Centre of Excellence for UK Medicines Manufacturing Skills will deliver training and outreach materials and programmes that addresses skills demands in the life sciences sector. The Centre will be run by an academic consortium of UK universities and…
Biocon Biologics enters a commercial collaboration with Eris Lifesciences
Biocon Biologics Limited have announced a long-term commercial collaboration with Eris Lifesciences to expand patient access to its portfolio of Metabolics, Oncology, and Critical Care products in India. This collaboration is in-line with Biocon Biologics’ strategy to unlock value from…
Madrigal Pharmaceuticals announces FDA approval of Rezdiffra
Madrigal Pharmaceuticals have announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3…
Zephyr AI Raises $111 Million in Series A Financing
Zephyr AI, Inc. have announced it has successfully closed a $111 million Series A funding round with participation from Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group, among others. The company is developing improved data federation tools…
Scotland’s Life Sciences Sector Poised for Growth
Further investment in high quality lab and research space is vital if the life sciences sector in Scotland is to continue to grow, according to leading real estate advisor CBRE. Speaking at an event in Edinburgh, Chris Dougray, Head of…
Novartis Acquires IFM Due for $835 million
IFM Therapeutics have announced that Novartis has exercised its option to acquire all of the outstanding capital stock of IFM Due, a subsidiary company of IFM. Launched in February 2019, with a focus on developing small molecules that inhibit the cGAS-STING pathway,…
Ricoh and ERS Genomics Enter into CRISPR/Cas9 License Agreement
Ricoh Company, Ltd. have announced a non-exclusive licensing agreement in the USA and Japan with ERS Genomics Limited for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS Genomics. CRISPR/Cas9 stands as a breakthrough gene editing technology, enabling…
.jpg?cb=edd73a132b8fe7aadbadc4106f034a17&w=1200)
Allumiqs and Prolytix form strategic partnership
Allumiqs and Prolytix, have announced their long-term, strategic partnership focused on delivering collaborative and integrated solutions to help customers optimise drug development pipelines. Together the partners empower customers with bioanalytical solutions to advance drug candidates from the early R&D phases through to…
SGD Pharma Successfully Trials Hydrogen Burners at Saint-Quentin-Lamotte Plant
SGD Pharma recently started a two-week trial using 100% hydrogen burners for industrial-scale glass production. The trial, conducted at SGD Pharma’s Saint-Quentin-Lamotte (SQLM) manufacturing plant in France, was a resounding success and will inform SGD Pharma’s decarbonisation roadmap which aims to reduce CO2…
Merck Completes Acquisition of Harpoon Therapeutics
Merck, known as MSD outside of the United States and Canada, have announced the completion of the acquisition of Harpoon Therapeutics, Inc. Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon’s common stock will no longer be publicly traded or…
Wegovy Approved in the US for Cardiovascular Risk Reduction
Novo Nordisk have announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE) including cardiovascular…
Ubiquigent Enters Agreement with Nanna Therapeutics
Ubiquigent Limited have announced an agreement with Nanna Therapeutics. Under the terms of the agreement, Ubiquigent will provide Nanna with access to its deubiquitylase (DUB) focused drug discovery platform to support the development of novel therapeutics for human disease targets selected by…
New ML-Powered Solution to Increase Success Rates of Phase 3 Oncology Trials
PhaseV, a pioneer in causal machine learning (ML) for clinical trial analysis and optimisation, announced it has partnered with oncology- and hematology-focused clinical research organisation (CRO) iOMEDICO to launch a new virtual analytical framework solution for pharma and biotech companies that seek…
WHO Report Shows Increase in HIV Drug Resistance to Dolutegravir
The World Health Organization’s (WHO) latest HIV Drug Resistance (HIVDR) Report tells us where drug resistance is growing and offers recommendations for countries to monitor and respond to the potential challenges. The report shares some good news and some concerning…
.jpg?cb=a7d64626e38062b2486039989abe2ed0&w=1200)
Roche and Alnylam Report Positive Topline Results from Phase II KARDIA-2 Study
Roche and Alnylam recently announced that the Phase II KARDIA-2 study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension (high blood pressure) – the leading cause of cardiovascular disease worldwide – met its primary endpoint. People with…
Single Use Systems for Biopharmaceutical Production – The Need for Regulatory Alignment
Written by: Mike Ludlow, Market Development Manager, Life Sciences; Element Materials Technology. The growth in the development of biopharmaceuticals has impacted the study design required for the assessment of extractables and leachables deriving from polymeric components used for the storage and…
Empowering Women in the Pharma Packaging Boardroom
On International Women’s Day March 8th, it’s a prime opportunity to reflect on the status of women in the pharmaceutical packaging sector and address the pressing need for better representation in boardrooms worldwide. To help us outline on the evolving…
Samsung BioLogics and UCB Sign Third Drug Manufacturing Deal
Samsung BioLogics and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB’s anti-tau candidate to treat progressive supranuclear palsy, pending regulatory approvals. UCB’s anti-tau candidate is currently in Phase I clinical studies….
GSK Announce Positive Results from DREAMM-8 Phase III Trial
GSK have announced positive headline results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment…
Gilead and Merus Announce Collaboration
Gilead Sciences and Merus N.V. have announced a research collaboration, option and license agreement to discover novel dual tumour-associated antigens (TAA) targeting trispecific antibodies. Gilead and Merus agreed to collaborate on the use of Merus’ proprietary Triclonics platform along with Gilead’s oncology expertise to…
Pharma Explained: What is Keytruda (pembrolizumab)?
Keytruda is one of the most significant and popular pharmaceuticals in the world. We at EPM have attempted to answer all of the questions you have have in our latest Pharma Explained.
AstraZeneca Plans £650 Million Investment in UK
AstraZeneca has outlined plans to invest £650 million in the UK – helping boost the UK’s world leading Life Sciences sector and grow the economy. This significant investment will enhance public health protection and pandemic preparedness. AstraZeneca intends to invest…
Novo Nordisk Kidney Trial Finds Ozempic Reduces Risk of Kidney Disease-Related Events
Novo Nordisk have announced the headline results from the kidney outcomes trial FLOW. The announcement follows the decision to stop the trial early due to efficacy, which was announced on 10 October 2023, based on a recommendation from an Independent Data…
.jpg?cb=49f06e8126a42b404d0596479a006ec5&w=1200)
ViiV Healthcare Present HIV Injectable Clinical Trial Findings
GSK plc have announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, have announced positive findings from its phase I study showing that an investigational formulation of cabotegravir, known as cabotegravir…
Heidelberg Pharma Announce Financing Agreement with HealthCare Royalty
Heidelberg Pharma AG and HealthCare Royalty have announced that they have signed a royalty financing agreement. Formal closing conditions that are expected to be fulfilled in a timely manner must still be met. Heidelberg Pharma is eligible to receive up to…
Bayer Acquire $310 Million Heart Burn Drug
Bayer has acquired the exclusive marketing rights for acoramidis in Europe from Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V. Acoramidis is a highly potent and selective small molecule, orally administered transthyretin (TTR) stabiliser for the treatment of…
GSK Announces Dr Jeannie Lee as Non-Executive Director
GSK plc has announced that Dr Jeannie Lee has been appointed to the Board of the Company as a Non-Executive Director. Dr Jeannie Lee is currently the Phillip A. Sharp, PhD, Endowed Chair in Molecular Biology and Acting Chair of…
Prange Group and Adragos Pharma Acquire Fresenius Kabi Production Site
Image credit: Adragos Pharma. The Prange Group and its affiliate Adragos Pharma, one of Europe’s fastest growing CDMOs, has completed the acquisition transaction of Fresenius Kabi production site in Halden, Norway – a leading sterile pharmaceutical manufacturing unit. This strategic…
.jpg?cb=8b2dce76c7ac337173754766eb532277&w=1200)
Pfizer Oncology Hosts Innovation Day
Pfizer Inc. has outlined its strategic priorities for the newly formed Oncology organisation — and how its pipeline, Oncology expertise, and anticipated near- and mid-term catalysts are expected to position the company to grow strongly. “With the completion of the Seagen…
Lonza Q&A – European Pharmaceutical Manufacturer
This is the third and last in a series of interviews with a collection of subject matter experts (SMEs) operating throughout Lonza. We have, over the last six months, covered a range of topics that the company covers, and heard…
Q&A: Navigating the EU’s new HTA Regulation
Herbert Altmann, PhD, Head of Market Access, Pricing and Reimbursement at Cencora (formerly AmerisourceBergen). Jai: How early will pharmaceutical companies need to start their preparation for the implementation of the EU-HTA regulation (JCA (Joint Clinical Assessment)) Altmann: Companies should begin…
.jpg?cb=59cc8c1cc2f28ae7bfd2397236582053&w=1200)
Boston Scientific Receives FDA Approval for the AGENT
Boston Scientific Corporation have announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing…
Clinigen Launch ‘What is Possible?’ Campaign
Clinigen have launched a new campaign called ‘What is Possible?’ to help empower patients and medical professionals to ask what more is possible in the treatment of rare diseases. There are over 7,000 rare diseases impacting over 300 million people…
PharmaKure Announces Collaboration with Sheffield Hallam University
PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease (AD) and other neurodegenerative diseases, have announced a new epigenetics collaboration with Sheffield Hallam University. This partnership will focus on ‘gene-based environmental biomarkers’, known as epigenetic markers, for calculating risk…
Neomorph Announce Novo Nordisk Collaboration
Neomorph, Inc. have announced it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and commercialise molecular glue degraders. Neomorph, a biotechnology company solving critical problems in human health through the discovery of novel…
Amneal Pharmaceuticals Enter Agreement with Zambon Biotech
Amneal Pharmaceuticals, Inc. have announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group, for IPX203 in the European Union, United Kingdom, and Switzerland. IPX203 is a novel, oral formulation of…
.jpg?cb=b8fe9e7a202b5cc78740fe5e975d2f4d&w=1200)
Telix Acquire IsoTherapeutics – European Pharmaceutical Manufacturer
Telix has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and…
Bristol Myers Squibb Acquire RayzeBio for $4.1 Billion
Bristol Myers Squibb has completed its acquisition of RayzeBio, Inc. With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. “We are…
SGD Pharma Awarded 2024 Gold EcoVadis Rating
SGD Pharma has achieved a gold medal in EcoVadis’ 2024 sustainability ratings. Building upon previous years, SGD Pharma’s score of 77 puts the business in the 98th percentile for manufacturers of glass and glass products. EcoVadis, the world’s most trusted provider…
Aptamer and Neuro-Bio Enter Second Phase of Alzheimer’s Test Development
Aptamer Group plc announces the second phase of its on-going partnership with Neuro-Bio, an Oxfordshire-based biotechnology company with a therapeutic focus on neurodegenerative disease, to develop Optimer binders for a lateral flow test for the early diagnosis of Alzheimer’s disease. This…
Capsules: Contributing to the Broader Landscape of Product Differentiation
Today’s healthcare market is overflowing with myriad products, making it increasingly difficult for businesses to stand out. This is particularly true for oral dosage forms, which – currently – account for over 80% of the market. Unlike prescription drugs,…
Grifols Announces Clinical Trial Results
Grifols has announced that Biotest’s positive topline results from AdFIrst, its phase 3 clinical trial of its fibrinogen concentrate (FC), BT524, advance this potential treatment for acquired fibrinogen deficiency (AFD), an underserved growth market. The FC from Biotest, a Grifols Group company, met…
PhaSER Biomedical Awarded $2.3m Gates Foundation Grant
PhaSER Biomedical (PhaSER) has received a grant totalling $2.3m to continue its pioneering work in accelerating drug discovery and development from the Bill & Melinda Gates Foundation. PhaSER will provide 8HUM transgenic mouse models, humanised for key pathways involved in…
MIP Discovery Closes £7m Series A Financing
MIP Discovery has closed a £7m Series A financing round led by Mercia Ventures. Existing investor Calculus Capital also participated in the round, along with Angel investors. The investment marks a pivotal change for MIP Discovery as the Bedfordshire-based company refocuses its…
UK Universities to Share £1.7 Million Oral Therapeutics Development Investment
A team of academics from Aston University, the University of Nottingham and King’s College London has secured a £1.7m grant to engineer bioinspired artificial nanoparticles that can be used for oral drug delivery. Oral administration is the preferred way of…
RSSL Announces New Innovation Hub
RSSL have announced plans to launch its new Innovation Hub, a dedicated platform to help small- and medium-sized biotech organisations de-risk and accelerate the development of cutting-edge products. RSSL’s Innovation Hub will be a supportive ecosystem for early-stage biotech companies, providing…
5 Tips to Reduce Costs in Process Cooling Systems
Refrigeration accounts for a high proportion of overall site energy costs, most notably cooling for pharmaceutical processes where up to 90% of energy costs can be accounted for by refrigeration. Ralph Howes, Cold Store Major Accounts Manager, ICS Cool Energy gives us…
BioAscent Invests in New Protein Production Facility
BioAscent has opened its state-of-the-art protein production facility in an event officiated by Professor Michael Barrett OBE. The new facility marks the latest key investment the company has made, further strengthening its in-house drug discovery capabilities with the ability to…
French Startup Bioptimus Launched – European Pharmaceutical Manufacturer
French startup Bioptimus emerged from stealth following a seed funding round of $35M. Under the leadership of Professor Jean-Philippe Vert, PhD, Bioptimus unites a world-class team of scientists from Owkin and Google DeepMind alumni to transform biology with cutting-edge AI foundation model…
NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben
NorthSea Therapeutics B.V. have announced the dosing of the first patient in its Phase 2a clinical trial of Orziloben (NST-6179) in intestinal failure-associated liver disease (IFALD), an orphan liver disease affecting individuals on prolonged intravenous (parenteral) nutrition (PN). The trial is a…
.png?cb=1addb4e0a79c7c95924471fe765c73c1&w=1200)
4 Reasons You Need Digital Production Records Now
Electronic production records give you a holistic view of your manufacturing operations, which is essential to achieving your key performance indicators (KPIs), such as zero defects in manufacturing, faster time to market, high customer satisfaction, a competitive advantage, etc. Read this…
Real-time sublimation front advance monitoring system for GMP freeze-dryers using wireless single use probes as a PAT tool
The advance of the sublimation front during primary drying in a freeze-drying process is one of the most critical parameters whose control is key to understand the drying kinetics for cycle development and validation as well as to ensure process…
Cum pot face o detoxifiere corporală?
detoxifiere corporală Detoxifierea este procesul natural al organismului de eliminare a toxinelor. Este o activitate continuă, realizată de ficat, rinichi, intestine, sistemul limfatic, piele și plămâni. Sănătatea unei persoane, obiceiurile alimentare și stilul de viață influențează cât de bine funcționează…
Freudenberg Medical Establishes Second Production Facility in Costa Rica
Freudenberg Medical is to establish a second manufacturing site in Costa Rica. With this $25 million investment the company is expanding its technologies to deliver increasingly complex products to its global customer base. “We are proud to be one of the…
GSK Acquires Aiolos Bio – European Pharmaceutical Manufacturer
GSK have announced that it has completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. As previously announced, the acquisition of Aiolos includes AIO-001, a potentially…
Integrated CMC Solutions in the Complex Biologics Space
The biopharmaceutical industry is undergoing a shift propelled by intricate biologics and their impact on global healthcare. With advancements in technology and subsequent therapies, particularly in antibody-based therapeutics, the industry’s landscape is witnessing a surge in innovative modalities, such as…
FUJIFILM Healthcare Europe Unveils ECHELON Synergy MRI Scanner
FUJIFILM Healthcare Europe has unveiled the ECHELON Synergy, a revolutionary MRI scanner for efficient, high performance imaging with optimal patient comfort. The 1.5 Tesla superconductive system employs AI-powered Synergy deep learning reconstruction (DLR) to enhance the sharpness of images and the speed of…
.jpg?cb=52a2c86b033286f71f596042130cda9f&w=1200)
Record Attendance at Pharmapack Europe
The drug delivery and packaging industry is poised for a promising 2024 following Pharmapack Europe held January 24th and 25th. Pharmapack recorded a joint record attendance of 5,500 and saw a strong resurgence in industry confidence in the Pharmapack Index; many new…
Preparing for the Quantum Revolution in Life Sciences
Written by: Bryan Hill (Global / Americas), Gaga Syal (GGM) & Rohit Alimchandani (UK) – Cognizant. For life sciences organisations, the pressure to speed up the time to market of new drugs and therapies continues at pace, alongside the need to reduce the cost…
The Complexities and Demands of Low Volume High Value Shipments
Written by: Andy Clarke, Country Manager (UK), YSDS. Low Volume, High Value The low volume life science market has significant complexities – an educated understanding of Good Distribution Practice (GDP) methods and processes is required before any shipments can commence,…
Enabling Investment in Digital and AI-Driven Medical Imaging
Artificial intelligence (AI) has the potential to radically alter the field of healthcare, and it’s already enhancing medical imaging. Penny Pinnock, Siemens Financial Services (SFS), explores how more efficient and accurate technology is contributing to improved healthcare outcomes and helping…
Osivax Announce First-in-Human Phase 1 Vaccination Trial
Osivax have announced that the first participant has been vaccinated in its new Phase 1 trial (NCT06128382) evaluating OVX033, a broad-spectrum sarbecovirus vaccine candidate. Recently, preclinical data published in Frontiers in Immunology demonstrated OVX033’s proof of cross-protection against three SARS-CoV-2 variants of concern. In…
Chiesi Announce Carbon Neutral Respiratory Portfolio
Chiesi Ltd, a Manchester-based biopharmaceutical company, has today announced a carbon neutral respiratory portfolio. Chiesi has already committed to a series of projects that will lead to a reduction of 90% direct greenhouse gas emissions generated, as well as emissions associated…
Ipsen’s Onivyde Approved by FDA
Ipsen have announced that the U.S. FDA has approved the supplemental new drug application for Onivyde (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as a first-line treatment in adults living with metastatic pancreatic adenocarcinoma (mPDAC). This is the second approval for…
AbbVie Complete Acquisition of ImmunoGen
AbbVie has completed its acquisition of ImmunoGen. “Together with ImmunoGen, we have the potential to continue redefining the standard of care for those living with cancer,” said Robert A. Michael, president and chief operating officer, AbbVie. “The addition of ImmunoGen’s treatment for…
PanTera Signs Actinium-225 Agreement with Bayer
PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of alpha-emitting radioisotopes, have announced the signing of a capacity reservation agreement with Bayer for the supply of actinium-225 (225Ac) starting in the second half of…
Biogen Receive European Commission Approval for SKYCLARYS
Biogen Inc. have announced the European Commission (EC) has authorised SKYCLARYS (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and older. SKYCLARYS is the first treatment approved within the European Union for this rare, genetic,…
Chanelle Pharma Acquired by Exponent
Chanelle Pharma has been sold by its founder Michael H Burke to Exponent, a leading private equity firm. Headquartered in Loughrea, Co. Galway, Chanelle Pharma is Ireland’s largest indigenous manufacturer of generic pharmaceuticals for animal and human health. The terms of…
Novartis Cosentyx Approved by Scottish Medicines Consortium
Novartis announced that, following positive advice from the Scottish Medicines Consortium (SMC), Cosentyx (secukinumab) is now available in Scotland on the NHS. It is licensed for adults with active moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately…
Telix Pharma to Acquire QSAM Biosciences
Telix has announced it has entered into an agreement to acquire QSAM Biosciences, Inc. and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer. 153Sm-DOTMP is a novel…
Zetta Genomics Raise Additional £1.8 Million
Zetta Genomics, has expanded its second seed round – securing an additional £1.8 million and strengthening investor expertise. Demonstrating continued confidence from first-round VCs, the expansion also attracts fresh investment from diagnostics start-up specialist We Venture Capital, as Zetta Genomics –…
Carb-X to Fund Visby Medical
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to $1.8 million to biotechnology company, Visby Medical, to develop a portable rapid polymerase chain reaction (PCR) diagnostic to detect the presence of the pathogen that causes gonorrhea, Neisseria gonorrhoeae (NG),…
Quibim Launch QP Insights – European Pharmaceutical Manufacturer
Quibim, a global company pioneering imaging biomarkers for precision medicine, is announcing the launch of a new product, QP-Insights, which enables researchers to leverage clinical imaging data throughout drug development programs. QP-Insights was designed alongside researchers to provide a comprehensive…
Samsung Biologics Partners with LegoChem Biosciences
Samsung Biologics have announced it has signed a partnership agreement with LegoChem Biosciences, a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs. Under the terms of the deal, Samsung Biologics will provide antibody development and drug…
Eczema and Our Evolving Environment
Nicholas Panico, President Scientific and Regulatory Affairs, Symbio Proinnovera Our skin is our body’s first line of defence against the elements, and as the world around us changes, for better or worse, so too does our dermatological health. For those…
Bridgebio Pharma and Kyowa Kirin Announce $100 Million Partnership
BridgeBio Pharma, Inc. and Kyowa Kirin Co., Ltd have announced a partnership wherein BridgeBio’s affiliate, QED Therapeutics, grants Kyowa Kirin an exclusive license to develop and commercialise infigratinib for achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan. In exchange, BridgeBio will…
.jpg?cb=e94578aeb944c47bb013bcd492a37996&w=1200)
GSK’s RSV Vaccine Accepted Under Priority Review in USGSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted under priority review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. If approved, GSK’s RSV vaccine would be the first vaccine available to help protect this population. Arexvy is currently approved in the US in adults aged 60 and over for the prevention of lower respiratory tract disease (LRTD) caused by RSV. The application is supported by positive results from a phase III trial [NCT05590403]4 evaluating the immune response and safety of GSK’s RSV vaccine in adults aged 50-59, including those at increased risk for RSV-LRTD due to underlying medical conditions. GSK used a Priority Review Voucher to reduce the US FDA review period of a supplemental Biologics License Application (sBLA) by four months. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is 7 June 2024. The burden of RSV disease in adults is likely to be underestimated due to lack of awareness, a lack of standardised testing, and under-detection in surveillance studies.5 People with underlying medical conditions, such as chronic obstructive pulmonary disease (COPD), asthma, chronic heart failure6 and diabetes,7 are at increased risk for RSV disease. RSV can exacerbate these conditions and lead to pneumonia, hospitalisation, or death.8
GSK plc have announced that the US Food and Drug Administration (FDA) has accepted under priority review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk…
.jpg?cb=542b5a7a0bc1cba535879176731c0065&w=1200)
AstraZeneca Invest $300m in US Manufacturing Facilities
AstraZeneca is investing $300 million in a state-of-the-art facility in Rockville, MD to launch its life-saving cell therapy platforms in the US for critical cancer trials and future commercial supply. More than 150 new highly skilled jobs will be created…
Accent Therapeutics Announce $75m Series C Financing
Accent Therapeutics have announced the closing of a $75 million Series C financing. The financing was led by Mirae Asset Capital Life Science, with participation from other new investors, Bristol Myers Squibb and Johnson & Johnson Innovation – JJDC, Inc. as…
Medidata and Sanofi Vaccines Extend Collaboration
Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, and Sanofi Vaccines, have announced a collaboration to harness Medidata eCOA to deploy in vaccine studies. This builds on Medidata and Sanofi’s longstanding, successful experience using Medidata…
Aston University launches SPARK The Midlands
Aston University has hosted an event to celebrate the launch of SPARK The Midlands, a network which aims to bridge the gap between medical research discoveries of novel therapeutics, medical devices and diagnostics, and real-world clinical use. More than 40 people…
Novo Nordisk To Expand Weight Loss Drug Manufacturing with $11bn Catalent Deal
Novo Nordisk have announced that the company has agreed to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction where Novo Holdings has agreed to acquire Catalent, Inc. (Catalent), a global contract development and manufacturing…
SGD Pharma Introduce Type I Tubular Vials Featuring Corning’s Velocity Vial Coating
SGD Pharma has announced its new range of high-quality Type I injectable vials in tubular glass with the added external low-friction coating developed by Corning thanks to an exclusive co-development partnership. SGD Pharma’s vial-converting expertise is combined with Corning’s proprietary glass-coating technology to…
Enterprise Therapeutics Closes £26 million Series B Funding
Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, have announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round,…
Cristalia Products with Nemera’s Reusable Pen Injector Commercialised in Brazil
Cristalia’s human growth hormone will be administered with CRISPEN. Approved by ANVISA1, CRISPEN is part of Nemera’s state-of- the-art pen injector platform PENDURA AD. The advantages of the pen are several, according to Monique Samaan, Cristalia’s Biotechnology Scientific Manager. “You can…
An Interview with LogiPharma’s Will Robinson
We caught up with LogiPharma’s Will Robinson to discuss one of their recent sustainability reports, supply chains, and what the pharma world needs to prioritise throughout 2024. Jai: Will Robinson, great to have you with us. Would you mind giving…
Vivet Therapeutics Receive €4.9 Million to Advance Development of Gene Therapy
Vivet Therapeutics have announced the financing of €4.9 million received from the French government to advance the development of a gene therapy for the treatment of cerebrotendinous xanthomatosis (CTX), a rare neurodegenerative disease. This funding is from the “Innovations in biotherapies”…
Central Research Laboratories Expanding Production Capacity
Central Research Laboratories (CRL) have announced that due to increased and steady demand for its Single-Use Beta Bags, it will be expanding the production capacity at its Red Wing, MN, manufacturing facility. To facilitate the expansion, CRL reconfigured its clean-room area and…
Unravelling the Potential of Organoids in Cancer Research: Challenges and Solutions
Joseph Boyd, PhD., and Vi Chu, Ph.D., Cell Biology R&D, Life Science Business of Merck. Organoids—complex, multicellular, 3-dimensional in vitro cell models used in biomedical research that closely mimic in vivo organs—are a powerful way to study drug responses, disease progression and more. These…
The Shape of the Pharmaceutical Industry in 2024: Trends and Predictions from Sharp
Reaching key milestones with pivotal shifts in treatment modalities and the reshaping of drug development, manufacturing and distribution – 2023 was a significant year for the pharmaceutical industry. Entering 2024, these trends are set to drive the industry forward, impacting…
NeoPhore Raise Additional £9.6m in Series B Financing
NeoPhore Limited have announced a further extension of £9.6m (approx. USD $12.2m) to its Series B financing round. With participation from its existing syndicate, CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG, and the addition…
Aurum Biosciences Raise £730k in Fresh Investment
Scottish biopharmaceutical company Aurum Biosciences has raised almost £730,000 in the first tranche of a new round of equity funding aimed at further developing its state-of-the-art therapeutic and diagnostic technology and setting up fresh success in 2024. The funding round…
Almirall and Microsoft Announce Partnership
Almirall S.A., have announced a strategic partnership with Microsoft to drive innovation and digital transformation, advance the research of medical solutions for dermatological diseases, and accelerate the digital transformation of the company. During this three-year collaboration, Almirall and Microsoft Industry Solutions,…
Q&A: Recipharm – European Pharmaceutical Manufacturer
We at EPM HQ, with the help of ramarketing, caught up with Uwe Hanenberg, Head of Product Development, Oral Solid Dose, Recipharm to discuss all things OSD! EPM: You’ve recently announced investment in your new analytical lab, can you tell…
Asimov Launches LV Edge Packaging System
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, have announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces the supply chain risk of lentiviral production. The ready-to-transfer system minimises…
FUSE-AI Launches Groundbreaking AI Algorithm for Radiology
FUSE-AI GmbH, an innovator in artificial intelligence for radiology, have announced its AI software “Prostate.Carcinoma.ai” has received EU Medical Device Regulation (MDR) 2017/745 IIa certification. As of January 2024, the company is authorised to distribute its software as a medical…
ACG Becomes World’s First Capsule Manufacturing Factory to Join the Global Lighthouse Network Community 2023-24
ACG, the world’s largest integrated supplier and service provider to the pharmaceutical industry, celebrated the inclusion of its capsule manufacturing facility in Pithampur, India, into the esteemed Global Lighthouse Network (GLN) by the World Economic Forum at the 54th Annual Davos…
.jpg?cb=f20d8ebdf3d917adf46d6a5e03c06c9e&w=1200)
GDMC Secures US$21 Million Growth Capital Funding
Genetic Design and Manufacturing Corporation (GDMC), a design and manufacturing organisation that focuses on next generation advanced genetic therapies, have announced a Series A funding of $21 million. The funding round is led by Celadon Partners, an Asia private equity firm…
Sharp Joins the Science Based Targets Initiative
Sharp has announced that it has committed to the Science Based Targets initiative (STBi) in a significant step towards reducing greenhouse gas emissions across the company. Sustainability continues to be a priority for Sharp, addressing the increasing demand for evidence of…
Kyowa Kirin Completes Acquisition of Orchard Therapeutics
Kyowa Kirin Co., Ltd. has successfully completed the acquisition of Orchard Therapeutics. The acquisition of all outstanding shares of Orchard Therapeutics by way of a Scheme of Arrangement procedure under the UK Companies Act 2006 was completed on January 24, 2024,…
UK Neobank Science Card Collaborates with UCL Mechanical Engineering
Science Card, the home of Britain’s first e-money current accounts dedicated to accelerating science and innovation, has announced the launch on its platform of a groundbreaking research project on neurodegenerative diseases, in collaboration with UCL’s Department of Mechanical Engineering. This…
Synnovation Therapeutics Launch $102 Million to Advance Clinical-Stage Pipeline
Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimised to achieve best-in-class pharmacology against highly validated disease targets, launched with a $102 million Series A. The financing was led by Third Rock Ventures with participation from Nextech, Lilly…
Cognizant and Takeda Expand Agreement to Modernise Tech Infrastructure
Cognizant have announced an expanded agreement with Takeda a global biopharmaceutical company, to support the company’s digital transformation strategy by reinforcing and supporting its technology efforts. Together, Takeda and Cognizant will embark on a new project to attract additional technology talent and help Takeda further…
Cherwell Launches Redipor Beta Bags to Support Continuous Manufacturing of Sterile Medicinal Products
Cherwell, cleanroom microbiology solutions expert, has launched the Redipor Beta Bag to ensure the safe transfer of ready-to-use gamma-irradiated prepared media into sterile manufacturing environments. This new multiple-use product transfer bag can reduce risk, cost and time in environmental monitoring (EM)…
Pharmapack Europe Awards Winners 2024
Pharmapack Europe have announced the winners of the prestigious 2024 Pharmapack Awards spanning four categories across two dedicated awards. The Health Product Awards are open to the entire pharma industry – with winners in ‘eco-design’ and ‘patient-centric design’ – while the Exhibitor…
Sheffield Hallam’s AWRC Unveils New Healthtech Accelerator Cohort
Sheffield Hallam University’s Advanced Wellbeing Research Centre (AWRC) has unveiled the companies set to join the 2024 cohort for its Advanced Wellbeing Accelerator programme. The prestigious six-month accelerator programme, which will support 10 start-ups and SMEs, was three times oversubscribed…
Virios Therapeutics to Develop Long Covid Therapy
Virios Therapeutics, Inc have announced plans for advancing IMC-2 (combination of valacyclovir and celecoxib) as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with long covid, also known as post-acute sequelae of SARS-CoV-2 infection (“PASC”). The Company is targeting…
BioLizard Announce Swiss Subsidiary and Service Offering for AI-Powered Digital Transformation of Life Science
BioLizard have announced the incorporation of BioLizard SA and the opening of new offices at Biopôle in Lausanne, home to one of the largest biotech hubs in Switzerland. Liesbeth Ceelen, PhD, CEO of BioLizard, said: “With our new subsidiary we will…
Sano Genetics Raises $11.4 Million
Sano Genetics, a software company accelerating precision medicine research, has raised $11.4 million in new funding, led by Plural with participation from existing investors including MMC Ventures, Episode 1 and Seedcamp. Founded by Patrick Short (CEO), Charlotte Guzzo (COO) and…
Pfizer’s Talazoparib Recommended by UK NICE for Advanced Breast Cancer
Pfizer’s Talazoparib has been recommended by UK NICE for advanced breast cancer. The recommendation reverses NICE’s earlier draft decision not to recommend talazoparib for adults with BRCA 1 or 2 mutated HER2-negative locally advanced or metastatic breast cancer after prior…
Carb-X To Fund Intravacc – European Pharmaceutical Manufacturer
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding US$633k to Intravacc to develop a vaccine that prevents Neisseria gonorrhoeae bacterial infections. Intravacc is a global contract development and manufacturing organisation located at the Utrecht Science Park Bilthoven in the Netherlands….
BGL Announce Sale of Source BioScience’s Stability Storage Business to Limerston Capital
Brown Gibbons Lang & Company (BGL) is pleased to announce the sale of Source Stability Storage, a UK-based biotech storage facility owned by parent company Source BioScience, to Limerston Capital, a London-based middle market private equity investment firm. Source Stability Storage will be renamed Astoriom. BGL’s Healthcare…
Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation
Synendos Therapeutics AG, a world leader in innovative Endocannabinoid System (ECS) treatments, has announced that it has received approval from the European Medicines Agency (EMA) to commence the Phase 1 ‘first-in-human’ clinical trial of its lead asset, SYT-510, a first-in-class inhibitor that modulates a…
.jpg?cb=08b09af9b9d11761dad30605e8e5a68a&w=1200)
AstraZeneca’s Voydeya (danicopan) Granted First-Ever Regulatory Approval in Japan
Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). It is indicated in Japan in combination with C5 inhibitor therapy when patients have had an insufficient response to such C5 inhibitors. Voydeya is a first-in-class, oral, Factor…
Bridgebio Pharma Secures Up To $1.25 billion
BridgeBio Pharma have announced strategic financing from Blue Owl Capital and Canada Pension Plan Investment Board, through a wholly owned subsidiary (CPPIB Credit) of CPPIB Credit Investments Inc., bringing in capital of up to $1.25 billion. With these transactions, BridgeBio…
Comanche Biopharma Raise $75 Million Series B Financing
Comanche Biopharma Corp have announced the closing of an oversubscribed $75 million Series B financing to advance its mission to develop and make globally available the first treatment targeting a root cause of preeclampsia. Existing investors GV (Google Ventures), F-Prime Capital,…
Inceptua Group and Cycle Pharmaceuticals Partner for a Free Goods Programme
Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd have announced that they have entered into a definitive merger agreement in which Sun Pharma, Taro’s controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro other than the…
Kindeva Drug Delivery Acquires Summit Biosciences
Kindeva Drug Delivery have announced that it has acquired Summit Biosciences Inc., an intranasal drug-delivery contract development and manufacturing organisation (CDMO), from its founding family shareholders. Established in 2009, Summit has an extensive track record of innovation in the unit dose nasal spray…
Pleco Therapeutics Receive FDA Orphan Drug Designation
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics BV’s lead compound, PTX-252 for the treatment of Acute Myeloid Leukaemia (AML). PTX-252 is a novel molecular entity developed to increase the sensitivity of cancer cells to chemotherapy. “We are very…
IBioIC Secures Funding to Continue Growth of Scotland’s Bioeconomy
The Industrial Biotechnology Innovation Centre (IBioIC) has been awarded long-term investment from the Scottish Funding Council (SFC), securing its position at the forefront of Scotland’s emerging bioeconomy. The commitment, announced by the First Minister on January 17th, will enable the…
Scopus AI to Help Researchers Navigate the World of Research
Elsevier, a global leader in scientific information and data analytics, has launches Scopus AI – a generative AI product to help researchers and research institutions get fast and accurate summaries and research insights that support collaboration and societal impact. Scopus AI is…
CME Automation Systems’ New Modular Automation System PACE
A new modular automation system for clinical trials drug delivery – now in operation at the Medical Manufacturing Innovation Centre (MMIC) in Strathclyde – is giving pharmaceutical and life sciences a game-changing insight into a future where new products can…
Santhera Receives UK Approval for AGAMREE
Santhera Pharmaceuticals have announced that AGAMREE (vamorolone) has been approved in the United Kingdom (UK) for the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older, independent of the underlying mutation and ambulatory status. The UK’s MHRA,…
Gates Foundation Announces Largest Budget Ever
The Bill & Melinda Gates Foundation have announced its largest annual budget to date as it works toward the goal of a healthier, more prosperous world for all. With global health budgets in decline overall, a portion of the additional…
Evotec and Crohn´s & Colitis Foundation Enter Agreement to Advance Drug Discovery
Evotec SE has joined forces with the Crohn’s & Colitis Foundation, the leading non-profit organisation focused on both research and patient support for inflammatory bowel disease, which includes Crohn’s disease and ulcerative colitis. Under the collaboration, Evotec joins forces with…
Monitoring Antibody Drug Safety and Efficacy in Preclinical and Clinical Development
John Cardone, Marketing Manager, Custom Antibodies, Bio-Rad Laboratories. Antibody-based therapeutics are a powerful modality developed for a range of diseases, including cancer, autoimmune disorders, and infections with over 170 antibodies in regulatory review or approved currently. An inherent high target…
China Approves Leqembi for the Treatment of Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. have announced that humanised anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI” has been approved in China as a treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia. Preparations for launch within…
WHO Certifies Cabo Verde Malaria-Free In Historic Milestone
The World Health Organization (WHO) has certified Cabo Verde as a malaria-free country, marking a significant achievement in global health. With this announcement, Cabo Verde joins the ranks of 43 countries and 1 territory that WHO has awarded this certification….
Ji Xing Pharmaceuticals Announced Acquisition of BIIB131 From Biogen
Ji Xing Pharmaceuticals a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved patients with serious and life-threatening diseases, have announced the acquisition of BIIB131 from Biogen, for global clinical development. BIIB131 is an investigational drug for acute ischemic stroke…
Cereno Scientific Signs CordenPharma To Manufacture CS1
Cereno Scientific have announced that an agreement has been signed with CordenPharma. CordenPharma is contracted to manufacture drug candidate CS1 in larger quantities, so-called scale-up manufacturing, needed to ensure supply to conduct the next clinical trial and later when approved for market…
Newcastle University, University of Edinburgh and Boehringer Ingelheim Involved In £30M Liver Health Study
The ADVANCE (Accelerating Discovery: Actionable NASH Cirrhosis Endpoints) study will be the most detailed observational study of its kind enrolling the largest number of patients and providing a detailed analysis of liver health, it involves Newcastle University, University of Edinburgh…
MSD to Acquire Harpoon Therapeutics
Merck, known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc have announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680…
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site
WuXi AppTec have announced the commissioning of two new peptide manufacturing plants, one at its Changzhou facility and another at the new Taixing site in China. This significant expansion has increased the company’s Solid-Phase Peptide Synthesis (SPPS) total reactor volume to 32,000 liters, addressing…
Iktos and Nerviano Medical Sciences Announce AI Collaboration
Iktos and Nerviano Medical Sciences S.r.l have announced a collaboration agreement in AI for unprecedented kinase project. As per the agreement, NMS will leverage Iktos’s expertise in drug design services, with the ultimate goal of identifying at least one promising…
.jpg?cb=1cb0939736dcf2442302e7822c334f6a&w=1200)
MOMA Therapeutics and Roche Announce Five-Year Discovery Collaboration
MOMA Therapeutics have announced a strategic collaboration and licensing agreement with Roche. This partnership provides Roche with access to MOMA’s proprietary KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer…
AbbVie and Umoja Biopharma Announce Strategic Collaboration
AbbVie and Umoja Biopharma (Umoja), an early clinical-stage biotechnology company, have announced two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja’s proprietary VivoVec platform. The first agreement provides AbbVie an exclusive option…
CordenPharma and pHLIP Announce Strategic Alliance
CordenPharma International and pHLIP, Inc. have announced their strategic alliance to collaborate in developing and commercialising the pHLIP-LNP targeted delivery platform for RNA-based and genetic therapeutics. The alliance will combine CordenPharma’s proprietary Lipid NanoParticle (LNP) technology and GMP manufacturing expertise with pHLIP’s…
UK MHRA’s new International Recognition Procedure Goes Live
From 1 January 2024, developers of new medicines can now submit applications via the MHRA’s new, International Recognition Procedure (IRP). The IRP will help bring life-saving medicines to UK patients and has been developed by the MHRA following the UK’s departure…
MediLink Therapeutics and Roche Announces Worldwide Collaboration and License Agreement
MediLink Therapeutics have announced that it has entered into a worldwide collaboration and license agreement with Roche on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumours. YL211 is a next-generation antibody-drug conjugate specifically…
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
Oragenics announces it has completed its previously announced acquisition of assets related to Odyssey Health’s proprietary neurological drug therapies and technologies. The acquired assets include ONP-002 and a unique nasal delivery device, Odyssey’s lead concussion asset, believed to be a first-in-class intranasal…
Component Washing: Better with Less
Reduced footprint, lower thermal and electrical consumption, water managed via recirculation systems and a concentrated jet drying system, anti-waste detergent dosing system: the new Aquaria by IMA Active launches a new generation of high-performance parts washers. Aquaria is the name…
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis
Voyager Therapeutics have announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA). Voyager will provide Novartis a target-exclusive license to access…
Roche to Acquire LumiraDx’s Point of Care Technology
Roche have announced that the entry into a definitive agreement to acquire select parts of the LumiraDx group related to LumiraDx’s innovative Point of Care technology. Following closing of the transaction, which is expected by mid-2024, the acquired entities will be fully…
Asahi Kasei Develop Novel Membrane System to Dehydrate Organic Solvents Without Heat or Pressure
Asahi Kasei has developed a novel membrane system for dehydrating organic solvents for pharmaceutical applications without the application of heat or pressure. This system can contribute to the optimisation of manufacturing processes in the pharmaceutical industry. The company has now…
Part 2: Lonza Q&A – European Pharmaceutical Manufacturer
Typically, Q&A’s are focused on a single topic or a single individual. To keep things interesting, here at EPM HQ, we devised a range of questions to put towards a varied group of subject matter experts at Lonza. Here’s what…
SGD Pharma: An Interview With Olivier Rousseau
SGD Pharma has been a leader in the moulded glass packaging market for a significant number of years. Central to their vision and plan is a persistent striving for excellence that runs through the company from top to bottom. To…